Medtronic cardiovascular organic growth in fiscal 2027
One-OffHealth & MedicineBusiness & Corporate12mnd
KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Above 10% 41%Koploper van 6 uitkomsten
Marktkwaliteit
25 / 100
Lage kwaliteit24u volume
—
Liquiditeit
€ 344,2
Lage liquiditeitSpread
10.0 pt
Brede spreadMarktdata
Bijgewerkt 3 minuten geleden
7 aug 26, 19:3031 aug 27, 4:00
Trends
0%
0%
0%
0%
0%
Regels
If Medtronic plc reports Above 6% cardiovascular organic revenue growth in fiscal 2027, then the market resolves to Yes.
Afwikkeling via:Fiscal.ai
- This market refers to the annual figure reported in Medtronic plc's full fiscal year or Q4 earnings release.
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company.
- All trademarks, logos, and brand names are the property of their respective owners.
- If Medtronic plc reports Above 7% cardiovascular organic revenue growth in fiscal 2027, then the market resolves to Yes.
- If Medtronic plc reports Above 8% cardiovascular organic revenue growth in fiscal 2027, then the market resolves to Yes.
Veelgestelde vragen
- Wat zijn de huidige kansen voor Medtronic cardiovascular organic growth in fiscal 2027?
- Kalshi prijst Above 10% op 41% per 4 september 2026.
- Wanneer wordt Medtronic cardiovascular organic growth in fiscal 2027 afgewikkeld?
- Medtronic cardiovascular organic growth in fiscal 2027 wordt naar verwachting op 31 augustus 2027 afgewikkeld.
- Hoe wordt Medtronic cardiovascular organic growth in fiscal 2027 afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If Medtronic plc reports Above 6% cardiovascular organic revenue growth in fiscal 2027, then the market resolves to Yes.
